References
- Bonifacio MJ, Archer M, Rodrigues ML, et al. (2002). Kinetics and crystal structure of catechol-o-methyltransferase complex with co-substrate and a novel inhibitor with potential therapeutic application. Mol Pharmacol 62:795–805
- Borges N. (2005). Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy. Expert Opin Drug Saf 4:69–73
- Buck K, Ferger B. (2010). l-DOPA-induced dyskinesia in Parkinson's disease: a drug discovery perspective. Drug Discov Today 15:867–75
- Cao W, Guo XW, Zheng HZ, et al. (2012). Current progress of research on pharmacologic actions of salvianolic acid B. Chin J Integr Med 18:316–20
- Deane KH, Spieker S, Clarke CE. (2004). Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev 18:CD004554
- Dingemanse J. (2000). Issues important for rational COMT inhibition. Neurology 55:S24–7
- Du GH, Qiu Y, Zhang JT. (2000). Salvianolic acid B protects the memory functions against transient cerebral ischemia in mice. J Asian Nat Prod Res 2:145–52
- Haasio K. (2010). Toxicology and safety of COMT inhibitors. Int Rev Neurobiol 95:163–89
- Kang KS, Wen Y, Yamabe N, et al. (2010). Dual beneficial effects of (-)-epigallocatechin-3-gallate on levodopa methylation and hippocampal neurodegeneration: in vitro and in vivo studies. PLoS One 5:e11951
- Li M, Zhao C, Wong RN, et al. (2004). Inhibition of shear-induced platelet aggregation in rat by tetramethylpyrazine and salvianolic acid B. Clin Hemorheol Microcirc 31:97–103
- Li X, Yu C, Lu Y, et al. (2007). Pharmacokinetics, tissue distribution, metabolism, and excretion of depside salts from Salvia miltiorrhiza in rats. Drug Metab Dispos 35:234–9
- Mannisto PT, Kaakkola S. (1990). Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease. Pharmacol Toxicol 66:317–23
- Mannisto PT, Kaakkola S. (1999). Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 51:593–628
- Muller T, Russ H. (2006). Levodopa, motor fluctuations and dyskinesia in Parkinson's disease. Expert Opin Pharmacother 7:1715–30
- Nagai M, Conney AH, Zhu BT. (2004). Strong inhibitory effects of common tea catechins and bioflavonoids on the O-methylation of catechol estrogens catalyzed by human liver cytosolic catechol-O-methyltransferase. Drug Metab Dispos 32:497–504
- Schapira AH, Obeso JA, Olanow CW. (2000). The place of COMT inhibitors in the armamentarium of drugs for the treatment of Parkinson's disease. Neurology 55:S65–8
- Truong DD. (2009). Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease. Clin Interv Aging 4:109–13
- Yang XN, Wang YJ, Liu YS, et al. (2008). Pharmacokinetics of salvianolic acids after intravenous injection, with and without Panax quinquefolium protopanaxadiol saponins, in rats. J Ethnopharmacol 117:408–14
- Zhang Y, Akao T, Nakamura N, et al. (2004). Magnesium lithospermate B is excreted rapidly into rat bile mostly as methylated metabolites, which are potent antioxidants. Drug Metab Dispos 32:752–7